ArticleJournal of cellular and molecular medicine2025
Evaluating the Potential of COL8A1 as a Therapeutic Target for Chemoresistance, Disease Progression, and a Prognostic Marker in Gastric Cancer.
Article in Journal of cellular and molecular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- COL8A1-positive cancer-associated fibroblasts are drivers of 5-fluorouracil resistance in colorectal cancer.Apoptosis : an international journal on programmed cell death · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
This study aimed to identify key genes associated with post-chemotherapy recurrence in gastric cancer patients. Gene expression data from multiple cohorts were analysed to determine differentially expressed genes between recurrent and non-recurrent cases. A prognostic risk model incorporating COL8A1, HSPB7 and SLIT2 was developed and validated across six independent cohorts. The risk score demonstrated significant associations with disease-free and overall survival, tumour grade and molecular subtypes. Notably, the risk score showed potential as a predictor of immunotherapy response, outperforming established markers such as microsatellite instability score and Epstein-Barr virus status. Analysis of the tumour immune microenvironment revealed a correlation between risk score and M2 macrophage infiltration. A nomogram integrating the risk score with clinical factors demonstrated high accuracy in predicting patient survival. Further investigation of COL8A1 revealed its significant role in gastric cancer cell proliferation, metastasis, and chemoresistance. In vitro and in vivo experiments showed that COL8A1 knockdown inhibited cancer cell growth, invasion, and metastasis while enhancing chemosensitivity. These findings provide valuable insights into the molecular mechanisms of gastric cancer recurrence and offer potential biomarkers for prognosis and treatment response prediction. The study highlights the importance of integrating genomic data with clinical information to improve patient stratification and personalised treatment strategies in gastric cancer management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.